Check out our top five most engaged social media posts from the year 2024.
FDA Approves Actemra Biosimilar
January 31st 2025Celltrion’s Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19—in the same dosages and formulations as its tocilizumab reference product.
FDA Approves Actemra Biosimilar
January 31st 2025Celltrion’s Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19—in the same dosages and formulations as its tocilizumab reference product.
485 Route 1 South,
Building F, Suite 210
Iselin, NJ 08830